Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
YCBD Stock Summary
In the News
cbdMD, Inc. to Host Conference Call to Discuss First Quarter of Fiscal 2024 Results
Charlotte, North Carolina--(Newsfile Corp. - February 8, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBD-PA), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a conference call at 4:20 p.m., Eastern Time, on Tuesday, February 13, 2024, to discuss the company's December 31, 2023 first quarter of fiscal 2024 financial results and business progress.
cbdMD, Inc. to Host Conference Call to Discuss September 30, 2023 Fourth Quarter and Fiscal Year 2023 Results
Charlotte, North Carolina--(Newsfile Corp. - December 20, 2023) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBD-PA), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a conference call at 4:20 p.m., Eastern Time, on Friday December 22, 2023, to discuss the company's September 30, 2023 fourth quarter of fiscal 2023 and full year of fiscal 2023 financial results and business progress.
cbdMD, Inc. to Host Conference Call to Discuss Third Quarter of Fiscal 2023 Results
Charlotte, North Carolina--(Newsfile Corp. - August 7, 2023) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a conference call at 4:30 p.m., Eastern Time, on Thursday August 10, 2023, to discuss the company's June 30, 2023 third quarter of fiscal 2023 financial results and business progress.
cbdMD, Inc. (YCBD) Q2 2023 Earnings Call Transcript
cbdMD, Inc. (NYSE:YCBD ) Q2 2023 Earnings Conference Call May 15, 2023 4:15 PM ET Company Participants Brad Whitford - VP of Finance Ronan Kennedy - Interim Chief Executive Officer and Chief Financial Officer Sibyl Swift - Chief Science Officer & VP Regulatory Affairs Conference Call Participants Anthony Vendetti - Maxim Group Operator Good afternoon. Welcome to cbdMD's, Inc. March 31, 2023, Second Quarter of Fiscal '23 Earnings Call and Update.
cbdMD, Inc. to Host Conference Call to Discuss Second Quarter of Fiscal 2023 Results
Charlotte, North Carolina--(Newsfile Corp. - May 10, 2023) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA) one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a conference call at 4:15 p.m., Eastern Time, on Monday, May 15, 2023, to discuss the company's March 31, 2023 second quarter of fiscal 2023 financial results and business progress.
cbdMD, Inc. (YCBD) Q4 2022 Earnings Call Transcript
cbdMD, Inc. (NYSE:YCBD ) Q4 2022 Earnings Conference Call February 13, 2022 4:15 PM ET Company Participants Brad Whitford - VP of Finance Ronan Kennedy - CFO and COO Kevin MacDermott - President Conference Call Participants Operator Good afternoon. Welcome to cbdMD Inc.'s December 31, 2022 First Quarter of Fiscal 2023 Earnings Call and Update.
cbdMD, Inc. (YCBD) Q4 2022 Earnings Call Transcript
cbdMD, Inc. (NYSE:YCBD ) Q4 2022 Earnings Conference Call December 15, 2022 4:15 PM ET Company Participants Ronan Kennedy - CFO and COO Kevin MacDermott - President Sibyl Swift - VP of Scientific and Regulatory Affairs Conference Call Participants Operator Good afternoon. Welcome to cbdMD Inc.'s September 30 Fourth Quarter and Fiscal 2022 Earnings Call and Update.
cbdMD, Inc. to Host Conference Call to Discuss Fourth Quarter and Fiscal 2022 Results
Charlotte, North Carolina--(Newsfile Corp. - December 14, 2022) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a conference call at 4:15 p.m., Eastern Time, on Thursday, December 15, 2022, to discuss the company's September 30, 2022 fourth quarter and fiscal 2022 financial results and business progress.CONFERENCE CALL DETAILSThursday, December 15, 2022, 4:15 p.m. Eastern Time
cbdMD, Inc. (YCBD) Q3 2022 Results - Earnings Call Transcript
cbdMD, Inc. (NYSE:YCBD ) Q3 2022 Results Conference Call August 11, 2022 4:30 PM ET Company Participants Ronan Kennedy - CFO and COO Scott Stephen - Chairman Kevin MacDermott - President Dr. Sibyl Swift - Vice President of Scientific and Regulatory Affairs Conference Call Participants Jeff Porter - Porter Capital Management Operator Good afternoon. Welcome to the cbdMD Inc.'s June 30, 2022 Third Quarter of Fiscal 2022 Earnings Call and Update.
cbdMD, Inc. (YCBD) CEO Marty Sumichrast on Q2 2022 Results - Earnings Call Transcript
cbdMD, Inc. (NYSE:YCBD ) Q2 2022 Earnings Conference Call May 13, 2022 4:30 PM ET Company Participants Ronan Kennedy - CFO and COO Marty Sumichrast - Chairman and Co-CEO Sibyl Swift - VP, Scientific & Regulatory Affairs Conference Call Participants Operator Good afternoon, and welcome to cbdMD, Inc.'s March 31, 2022, Second Quarter of Fiscal 2022 Earnings Call and Update. This afternoon, the company issued a press release that provided an overview of its second quarter of fiscal year 2022 results, which followed the filing of its quarterly report on Form 10-Q.
YCBD Financial details
YCBD Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-09-30
Metric | History | 2019-09-30 | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 59.5 | 42.7 | 36.43 | 26.67 | 11.94 | |
Net income per share | -114.29 | 12.85 | -19.16 | -55.8 | -11.34 | |
Operating cash flow per share | -38.69 | -10.87 | -11.54 | -11.27 | -2.13 | |
Free cash flow per share | -41.83 | -12.22 | -13.46 | -11.79 | -2.27 | |
Cash per share | 13.81 | 15.4 | 22.48 | 5.81 | 0.89 | |
Book value per share | 94.6 | 80.72 | 84.48 | 23.67 | 4.47 | |
Tangible book value per share | -97.36 | 2.93 | 19.13 | 10.24 | 2.87 | |
Share holders equity per share | 94.6 | 80.72 | 84.48 | 23.67 | 4.47 | |
Interest debt per share | 2.2 | 8.85 | 5 | 3.68 | 1.82 | |
Market cap | 70.83M | 88.28M | 114.27M | 13.45M | 2.08M | |
Enterprise value | 66.14M | 82.14M | 93.93M | 11.6M | 3.97M | |
P/E ratio | -1.56 | 7.01 | -4.88 | -0.18 | -0.09 | |
Price to sales ratio | 2.99 | 2.11 | 2.57 | 0.38 | 0.09 | |
POCF ratio | -4.61 | -8.28 | -8.11 | -0.9 | -0.48 | |
PFCF ratio | -4.26 | -7.37 | -6.95 | -0.86 | -0.45 | |
P/B Ratio | 1.88 | 1.11 | 1.11 | 0.43 | 0.23 | |
PTB ratio | 1.88 | 1.11 | 1.11 | 0.43 | 0.23 | |
EV to sales | 2.8 | 1.96 | 2.11 | 0.33 | 0.16 | |
Enterprise value over EBITDA | 3.4 | -1.8 | -7.4 | 0.3 | 0.54 | |
EV to operating cash flow | -4.3 | -7.7 | -6.66 | -0.77 | -0.92 | |
EV to free cash flow | -3.98 | -6.85 | -5.72 | -0.74 | -0.86 | |
Earnings yield | -0.64 | 0.14 | -0.2 | -5.51 | -11.01 | |
Free cash flow yield | -0.23 | -0.14 | -0.14 | -1.16 | -2.21 | |
Debt to equity | 0.02 | 0.11 | 0.06 | 0.15 | 0.41 | |
Debt to assets | 0.01 | 0.08 | 0.05 | 0.12 | 0.23 | |
Net debt to EBITDA | -0.24 | 0.13 | 1.6 | -0.05 | 0.25 | |
Current ratio | 4.24 | 3.08 | 5.28 | 3.03 | 1.73 | |
Interest coverage | 0 | 0 | -678.05 | 2.2K | 0 | |
Income quality | 0.3 | -0.85 | 0.6 | 0.21 | 0.19 | |
Dividend Yield | 0 | 0 | 0.02 | 0.3 | 1.76 | |
Payout ratio | 0 | 0.03 | -0.11 | -0.05 | -0.16 | |
Sales general and administrative to revenue | 0 | 0.55 | 0.49 | 0.45 | 0.4 | |
Research and developement to revenue | 0 | 0.01 | 0.03 | 0.02 | 0.01 | |
Intangibles to total assets | 0.81 | 0.69 | 0.64 | 0.44 | 0.2 | |
Capex to operating cash flow | 0.08 | 0.12 | 0.17 | 0.05 | 0.07 | |
Capex to revenue | -0.05 | -0.03 | -0.05 | -0.02 | -0.01 | |
Capex to depreciation | -4.31 | -1.83 | -1.04 | -0.23 | -0.1 | |
Stock based compensation to revenue | 0.11 | 0.05 | 0.07 | 0.03 | 0.01 | |
Graham number | 493.23 | 152.76 | 190.86 | 172.38 | 33.76 | |
ROIC | 0.47 | -0.21 | -0.16 | 0.92 | -2.19 | |
Return on tangible assets | -2.49 | 0.36 | -0.52 | -3.23 | -1.77 | |
Graham Net | -118.93 | -13.5 | 7.42 | 1.18 | -1.2 | |
Working capital | 12.03M | 16.02M | 29.59M | 10.73M | 3.4M | |
Tangible asset value | -38.7M | 2.88M | 23.35M | 13.59M | 5.81M | |
Net current asset value | -41.17M | -7.95M | 14.76M | 6.64M | 906.04K | |
Invested capital | 0.02 | 0.11 | 0.06 | 0.15 | 0.41 | |
Average receivables | 3.44M | 2.01M | 1.24M | 1.29M | 1.33M | |
Average payables | 1.75M | 2.94M | 2.91M | 2.51M | 1.97M | |
Average inventory | 2.21M | 4.45M | 4.81M | 4.64M | 4.15M | |
Days sales outstanding | 41.14 | 11.84 | 9.23 | 14.94 | 18.38 | |
Days payables outstanding | 120.7 | 67.06 | 75.01 | 56.89 | 75.81 | |
Days of inventory on hand | 171.84 | 108.3 | 126.46 | 118.88 | 161.19 | |
Receivables turnover | 8.87 | 30.83 | 39.56 | 24.43 | 19.86 | |
Payables turnover | 3.02 | 5.44 | 4.87 | 6.42 | 4.81 | |
Inventory turnover | 2.12 | 3.37 | 2.89 | 3.07 | 2.26 | |
ROE | -1.21 | 0.16 | -0.23 | -2.36 | -2.54 | |
Capex per share | -3.14 | -1.35 | -1.92 | -0.52 | -0.15 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q1
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 4.54 | 2.62 | 6.08 | 2.82 | 1.82 | |
Net income per share | -3.7 | 25.45 | -1.76 | -7.85 | -0.34 | |
Operating cash flow per share | -1.54 | -0.73 | -0.24 | -0.13 | -0.04 | |
Free cash flow per share | -1.67 | -0.69 | -0.34 | -0.19 | -0.1 | |
Cash per share | 3.25 | 0.72 | 2.83 | 0.89 | 0.51 | |
Book value per share | 19.82 | 10.84 | 25.56 | 4.47 | 2.38 | |
Tangible book value per share | 6.74 | 3.57 | 8.67 | 2.87 | 1.35 | |
Share holders equity per share | 19.82 | 10.84 | 25.56 | 4.47 | 2.38 | |
Interest debt per share | 3.44 | 1.8 | 3.96 | 1.81 | 1.14 | |
Market cap | 13.71M | 20.89M | 1.41M | 2.08M | 3.08M | |
Enterprise value | 14.94M | 23.46M | 2.55M | 3.97M | 4.94M | |
P/E ratio | -0.69 | 0.09 | -0.2 | -0.03 | -0.77 | |
Price to sales ratio | 2.25 | 3.35 | 0.23 | 0.36 | 0.57 | |
POCF ratio | -6.64 | -12.05 | -5.86 | -7.91 | -27.4 | |
PFCF ratio | -6.11 | -12.81 | -4.11 | -5.43 | -10.37 | |
P/B Ratio | 0.52 | 0.81 | 0.05 | 0.23 | 0.44 | |
PTB ratio | 0.52 | 0.81 | 0.05 | 0.23 | 0.44 | |
EV to sales | 2.45 | 3.76 | 0.42 | 0.69 | 0.92 | |
Enterprise value over EBITDA | -4.33 | -28.42 | -2.42 | 0.31 | -11.66 | |
EV to operating cash flow | -7.24 | -13.53 | -10.6 | -15.06 | -43.98 | |
EV to free cash flow | -6.66 | -14.38 | -7.43 | -10.34 | -16.64 | |
Earnings yield | -0.36 | 2.9 | -1.26 | -7.62 | -0.32 | |
Free cash flow yield | -0.16 | -0.08 | -0.24 | -0.18 | -0.1 | |
Debt to equity | 0.17 | 0.17 | 0.15 | 0.41 | 0.48 | |
Debt to assets | 0.13 | 0.13 | 0.12 | 0.23 | 0.22 | |
Net debt to EBITDA | -0.36 | -3.11 | -1.08 | 0.15 | -4.4 | |
Current ratio | 2.08 | 2.17 | 2.3 | 1.73 | 1.23 | |
Interest coverage | -138.95 | -719.75 | -1.46K | 470.96 | -2.39K | |
Income quality | 0.52 | 1.3 | 0.14 | 0.02 | 0.11 | |
Dividend Yield | 0.07 | 0.05 | 0.71 | 0.32 | 0 | |
Payout ratio | -0.2 | 0.02 | -0.57 | -0.04 | 0 | |
Sales general and administrative to revenue | 0.63 | 0.42 | 0.37 | 0.17 | 0.35 | |
Research and developement to revenue | 0.01 | 0.01 | 0 | 0 | 0 | |
Intangibles to total assets | 0.49 | 0.51 | 0.52 | 0.2 | 0.2 | |
Capex to operating cash flow | 0.09 | -0.06 | 0.43 | 0.46 | 1.64 | |
Capex to revenue | -0.03 | 0.02 | -0.02 | -0.02 | -0.03 | |
Capex to depreciation | -0.27 | 0.18 | -0.13 | -0.13 | 0.32 | |
Stock based compensation to revenue | 0.02 | 0.01 | 0.01 | 0.02 | 0.33 | |
Graham number | 40.6 | 78.77 | 31.81 | 28.08 | 4.24 | |
ROIC | -0.14 | 1.85 | -30.63 | -1.72 | -80.44 | |
Return on tangible assets | -0.27 | 3.69 | -0.11 | -1.22 | -0.08 | |
Graham Net | -1.32 | -1.28 | -1.41 | -1.2 | -1.3 | |
Working capital | 5.98M | 5.47M | 5.71M | 3.4M | 1.39M | |
Tangible asset value | 9.03M | 8.51M | 8.73M | 5.81M | 3.99M | |
Net current asset value | 2.39M | 2.25M | 2.85M | 906.04K | -692.46K | |
Invested capital | 0.17 | 0.17 | 0.15 | 0.41 | 0.48 | |
Average receivables | 1.17M | 1.03M | 1.14M | 1.16M | 1.16M | |
Average payables | 1.86M | 1.51M | 1.37M | 1.66M | 1.74M | |
Average inventory | 4.47M | 4.61M | 4.4M | 4.16M | 3.9M | |
Days sales outstanding | 13.29 | 16.75 | 16.35 | 19.17 | 18.45 | |
Days payables outstanding | 60.4 | 54.12 | 55.88 | 79.36 | 67.09 | |
Days of inventory on hand | 167.69 | 183.35 | 169.28 | 168.73 | 160.28 | |
Receivables turnover | 6.77 | 5.37 | 5.5 | 4.7 | 4.88 | |
Payables turnover | 1.49 | 1.66 | 1.61 | 1.13 | 1.34 | |
Inventory turnover | 0.54 | 0.49 | 0.53 | 0.53 | 0.56 | |
ROE | -0.19 | 2.35 | -0.07 | -1.76 | -0.14 | |
Capex per share | -0.13 | 0.04 | -0.1 | -0.06 | -0.06 |
YCBD Frequently Asked Questions
What is cbdMD, Inc. stock symbol ?
cbdMD, Inc. is a US stock , located in Charlotte of Nc and trading under the symbol YCBD
What is cbdMD, Inc. stock quote today ?
cbdMD, Inc. stock price is $0.93 today.
Is cbdMD, Inc. stock public?
Yes, cbdMD, Inc. is a publicly traded company.